Kennedy Capital Management’s Cross Country Healthcare CCRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-9,607
Closed -$238K 691
2023
Q3
$238K Buy
9,607
+226
+2% +$5.69K 0.01% 647
2023
Q2
$263K Buy
+9,381
New +$233K 0.01% 640
2020
Q2
Sell
-141,129
Closed -$951K 665
2020
Q1
$951K Buy
+141,129
New +$1.34M 0.04% 565
2018
Q2
Sell
-872,325
Closed -$9.69M 745
2018
Q1
$9.69M Buy
872,325
+681,801
+358% +$8.54M 0.19% 157
2017
Q4
$2.43M Buy
190,524
+135,163
+244% +$1.79M 0.04% 597
2017
Q3
$788K Buy
+55,361
New +$693K 0.01% 681
2016
Q4
Sell
-517,773
Closed -$6.1M 726
2016
Q3
$6.1M Buy
517,773
+215,609
+71% +$2.84M 0.12% 306
2016
Q2
$4.21M Buy
302,164
+112,628
+59% +$1.49M 0.09% 394
2016
Q1
$2.2M Buy
189,536
+66,338
+54% +$843K 0.04% 566
2015
Q4
$2.02M Buy
123,198
+22,965
+23% +$365K 0.04% 569
2015
Q3
$1.36M Buy
100,233
+53,233
+113% +$723K 0.03% 630
2015
Q2
$596K Buy
+47,000
New +$533K 0.01% 693

Other funds holding CCRN

Kennedy Capital Management's CCRN Position: Q4 2023 in Review

Kennedy Capital Management sold out of Cross Country Healthcare (CCRN) in Q4 2023, closing a stake of 9,607 shares — an estimated $238K sold.

Kennedy Capital Management first reported a position in CCRN in Q2 2015 and held it in 12 quarters. The position peaked at $9.69M in Q1 2018. 175 funds tracked by Wall St. Rank hold CCRN as of Q4 2023.

  • Kennedy Capital Management reported no remaining Cross Country Healthcare position as of Q4 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 9,607 Cross Country Healthcare shares in Q4 2023, an estimated $238K.
  • Kennedy Capital Management first reported a position in Cross Country Healthcare in Q2 2015 and held it in 12 quarters.
  • Kennedy Capital Management's Cross Country Healthcare position peaked at $9.69M in Q1 2018.
  • 175 funds tracked by Wall St. Rank held Cross Country Healthcare as of Q4 2023.

Based on Kennedy Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.